Mortality and treatment costs of hospitalized chronic kidney disease patients between the three major health insurance schemes in Thailand.
Thailand has reformed its healthcare to ensure fairness and universality. Previous reports comparing the fairness among the 3 main healthcare schemes, including the Universal Coverage Scheme (UCS), the Civil Servant Medical Benefit Scheme (CSMBS) and the Social Health Insurance (SHI) have been published. They focused mainly on provision of medication for cancers and human immunodeficiency virus infection. Since chronic kidney disease (CKD) patients have a high rate of hospitalization and high risk of death, they also require special care and need more than access to medicine. We, therefore, performed a 1-year, nationwide, evaluation on the clinical outcomes (i.e., mortality rates and complication rates) and treatment costs for hospitalized CKD patients across the 3 main health insurance schemes.



All adult in-patient CKD medical expense forms in fiscal 2010 were analyzed. The outcomes focused on were clinical outcomes, access to special care and equipment (especially dialysis), and expenses on CKD patients. Factors influencing mortality rates were evaluated by multiple logistic regression.



There were 128,338 CKD patients, accounting for 236,439 admissions. The CSMBS group was older on average, had the most severe co-morbidities, and had the highest hospital charges, while the UCS group had the highest rate of complications. The mortality rates differed among the 3 insurance schemes; the crude odds ratio (OR) for mortality was highest in the CSMBS scheme. After adjustment for biological, economic, and geographic variables, the UCS group had the highest risk of in-hospital death (OR 1.13;95 % confidence interval (CI) 1.07-1.20; p < 0.001) while the SHI group had lowest mortality (OR 0.87; 95 % CI 0.76-0.99; p = 0.038). The circumscribed healthcare benefits and limited access to specialists and dialysis care in the UCS may account for less favorable comparison with the CSMBS and SHI groups.



Significant differences are observed in mortality rates among CKD patients from among the 3 main healthcare schemes. Improvements in equity of care might minimize the differences.
Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen Province, 40002, Thailand. sirirt_a@kku.ac.th.
Sirirat
S
Anutrakulchai
Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen Province, 40002, Thailand.
Pisaln
P
Mairiang
Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen Province, 40002, Thailand.
Cholatip
C
Pongskul
Clinical Epidemiology Unit, Faculty of Medicine, Khon Kaen University, Khon Kaen Province, 40002, Thailand.
Kaewjai
K
Thepsuthammarat
Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen Province, 40002, Thailand.
Chitranon
C
Chan-On
Department of Biostatistics and Demography, Faculty of Public Health, Khon Kaen University, Khon Kaen Province, 40002, Thailand. bandit@kku.ac.th.
Bandit
B
Thinkhamrop
D000328:Adult; D000368:Aged; D015897:Comorbidity; D005260:Female; D017048:Health Care Costs; D017722:Hospital Charges; D006760:Hospitalization / Q000191:economics*; D006801:Humans; D007348:Insurance, Health / Q000191:economics*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis / Q000191:economics / Q000401:mortality; D051436:Renal Insufficiency, Chronic / Q000191:economics / Q000401:mortality / Q000628:therapy*; D013785:Thailand; D019472:Universal Health Insurance / Q000191:economics
Chronic kidney disease; Dialysis; Endstage renal disease; Healthcare equity; Healthcare scheme
Trends Microbiol. 2008 Dec;16(12):574-9
18964022
Nephrol Dial Transplant. 2012 Oct;27(10):3849-55
22759385
Health Res Policy Syst. 2013 Aug 06;11:25
23919275
J Med Assoc Thai. 2012 Jul;95 Suppl 7:S240-53
23130462
Adv Health Econ Health Serv Res. 2009;21:57-81
19791699
Australas epidemiol. 2010 Dec;17(3):24-26
22427738
Intern Med J. 2006 Mar;36(3):185-92
16503954
Kidney Int. 2011 Jan;79(2):210-7
20927036
Catheter Cardiovasc Interv. 2012 Sep 1;80(3):352-7
22566286
Clin J Am Soc Nephrol. 2012 Mar;7(3):409-16
22266573
Hematology. 2012 Apr;17 Suppl 1:S72-4
22507785
Cardiology. 2007;108(3):193-9
17095865
J Card Fail. 2007 Aug;13(6):422-30
17675055
J Med Assoc Thai. 2012 Jul;95 Suppl 7:S74-80
23130438
Zhonghua Xin Xue Guan Bing Za Zhi. 2009 Aug;37(8):729-33
20021928
J Med Assoc Thai. 2011 Sep;94 Suppl 4:S153-61
22043584
J Intern Med. 2010 Jul;268(1):40-9
20210836
Eur J Cardiothorac Surg. 2008 Aug;34(2):390-5; discussion 395
18502144
Soc Sci Med. 1999 Apr;48(7):913-23
10192558
N Engl J Med. 2004 Sep 23;351(13):1296-305
15385656
Am J Cardiol. 2004 Jun 15;93(12):1526-8
15194026
Hum Resour Health. 2015 Jul 18;13:59
26187375
Cost Eff Resour Alloc. 2006 Dec 30;4:21
17196110
Nephrol Dial Transplant. 2008 Jun;23 (6):1955-60
18083761
Rev Bras Cir Cardiovasc. 2011 Jul-Sep;26(3):319-25
22086567
BMJ Open. 2012 Nov 28;2(6):null
23192243
Rev Epidemiol Sante Publique. 2010 Jun;58(3):171-9
20430553
J Neurol Sci. 2011 Feb 15;301(1-2):46-50
21094955
Soc Sci Med. 2015 Nov;145:227-36
26452699